Wikisage, the free encyclopedia of the second generation, is digital heritage
Zonisamide: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
mNo edit summary |
||
| Line 5: | Line 5: | ||
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451432/ Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis] | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451432/ Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis] | ||
[http://ac.els-cdn.com/S071686401270295X/1-s2.0-S071686401270295X-main.pdf?_tid=015b25bc-89ef-11e7-8ccc-00000aacb35d&acdnat=1503704707_e514043afaffa54860aa6f4fa522df67 Tratamiento farmacológico de la obesidad Pharmacological obesity treatment] | |||
[[wikipedia:zonisamide]] | [[wikipedia:zonisamide]] | ||
Revision as of 23:43, 25 August 2017
zonisamide is a 1,2-benzisoxazole-3-methanesulfonamide, that was initally used as anticonvulsant drug and latter as Parkinson-drug
Zonisamide inhibits monoaminooxidaseand enhances motor perfomance and social activity
Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis Tratamiento farmacológico de la obesidad Pharmacological obesity treatment wikipedia:zonisamide